Intavis Peptide Services

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐖𝐞𝐞𝐤𝐥𝐲 𝐏𝐨𝐥𝐥 In peptide manufacturing, maintaining GMP compliance involves several critical challenges that require careful attention to detail. Which area do you find the most demanding? 𝐘𝐨𝐮𝐫 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐚𝐫𝐞 𝐯𝐚𝐥𝐮𝐚𝐛𝐥𝐞, 𝐬𝐨 𝐟𝐞𝐞𝐥 𝐟𝐫𝐞𝐞 𝐭𝐨 𝐬𝐡𝐚𝐫𝐞 𝐲𝐨𝐮𝐫 𝐭𝐡𝐨𝐮𝐠𝐡𝐭𝐬! #PeptideManufacturing #GMPCompliance #IntavisWeeklyPoll

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐨𝐮𝐧𝐝𝐮𝐩 "𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 𝐭𝐨 𝐈𝐦𝐩𝐫𝐨𝐯𝐢𝐬𝐞 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐃𝐫𝐮𝐠𝐬 𝐚𝐬 𝐍𝐞𝐱𝐭 𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬" 𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐦𝐚𝐢𝐧 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐢𝐧 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐢𝐧𝐠 𝐩𝐞𝐩𝐭𝐢𝐝𝐞-𝐛𝐚𝐬𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, 𝐚𝐧𝐝 𝐡𝐨𝐰 𝐜𝐚𝐧 𝐭𝐡𝐞𝐬𝐞 𝐛𝐞 𝐚𝐝𝐝𝐫𝐞𝐬𝐬𝐞𝐝? Peptide-based therapeutics face several challenges, including susceptibility to proteolytic degradation, poor membrane permeability, short half-life, and limited oral bioavailability, which limit their clinical efficacy. To address these issues, researchers have developed a variety of chemical modifications such as backbone modifications, which enhance the stability of peptide bonds, and side-chain modifications to improve peptide-receptor interactions and specificity. Termini protection, like N-terminal acetylation or C-terminal amidation, helps prevent enzymatic degradation. PEGylation and glycosylation are used to increase molecular size, reduce renal clearance, and enhance half-life. Cyclization is also employed to stabilize the peptide structure, reducing flexibility and improving resistance to proteolytic enzymes. These strategies collectively aim to improve the pharmacokinetics and therapeutic potential of peptide drugs. 𝐇𝐨𝐰 𝐚𝐫𝐞 𝐩𝐞𝐩𝐭𝐢𝐝𝐞-𝐛𝐚𝐬𝐞𝐝 𝐝𝐫𝐮𝐠𝐬 𝐛𝐞𝐢𝐧𝐠 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐟𝐨𝐫 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐮𝐬𝐞, 𝐚𝐧𝐝 𝐰𝐡𝐚𝐭 𝐫𝐨𝐥𝐞 𝐝𝐨𝐞𝐬 𝐝𝐫𝐮𝐠 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐩𝐥𝐚𝐲 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐩𝐫𝐨𝐜𝐞𝐬𝐬? Peptide-based drugs are being advanced through both chemical modifications and computational methods that optimize their design for clinical use. Computational tools aid in predicting peptide structure, stability, and interaction with biological targets, allowing for the design of more effective and stable peptides. In terms of drug delivery, innovative approaches like nanoparticle-based systems, such as liposomes and micelles, protect peptides from degradation and ensure targeted delivery. These systems enhance the bioavailability of peptides by improving their absorption through routes such as transdermal, oral, pulmonary, and nasal delivery. Nanocarriers further facilitate sustained release, enabling lower dosages and reduced side effects, which are critical for improving the clinical application of peptide-based therapies. Paper reference: Barman, P., Joshi, S., Sharma, S., Preet, S., Sharma, S., & Saini, A. (2023). Strategic approaches to improvise peptide drugs as next generation therapeutics. International journal of peptide research and therapeutics, 29(4), 61. #Peptides #DrugDevelopment #GMP #Neoantigen

Good luck and great success Christian Stumpp, MBA, Ph.D. . Our Head of Marketing and Business Development is attending #BioRN2024 today! feel free to reach out to discuss cool peptide project and #neoantigen #cancer #vaccines

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐍𝐞𝐰𝐬 "𝐂𝐞𝐥𝐥-𝐏𝐞𝐧𝐞𝐭𝐫𝐚𝐭𝐢𝐧𝐠 𝐏𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐓𝐫𝐚𝐧𝐬𝐥𝐨𝐜𝐚𝐭𝐞 𝐚𝐜𝐫𝐨𝐬𝐬 𝐭𝐡𝐞 𝐏𝐥𝐚𝐬𝐦𝐚 𝐌𝐞𝐦𝐛𝐫𝐚𝐧𝐞 𝐛𝐲 𝐈𝐧𝐝𝐮𝐜𝐢𝐧𝐠 𝐕𝐞𝐬𝐢𝐜𝐥𝐞 𝐁𝐮𝐝𝐝𝐢𝐧𝐠 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐩𝐬𝐞" The authors investigates the mechanism by which 𝐜𝐞𝐥𝐥-𝐩𝐞𝐧𝐞𝐭𝐫𝐚𝐭𝐢𝐧𝐠 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬 (CPPs) like nonaarginine (R9) and cyclic CPPs (CPP12 and CPP17) traverse the plasma membrane of mammalian cells. Through time-lapse confocal microscopy, the study provides direct evidence that these CPPs use a vesicle budding-and-collapse (VBC) mechanism for membrane translocation. The research identifies four distinct nucleation zones (NZs) on the plasma membrane, where CPPs cluster with phospholipids, leading to vesicle formation and subsequent collapse, releasing CPPs into the cytosol. This mechanism reconciles previous conflicting models of CPP entry, showing that CPPs can penetrate cell membranes without the need for endocytosis. The study underscores the VBC mechanism as a critical pathway for CPP-mediated drug delivery, offering insights into the dynamics of membrane translocation and cargo delivery, potentially improving drug design strategies. Paper reference: Sahni, A., Ritchey, J. L., Qian, Z., & Pei, D. (2024). Cell-Penetrating Peptides Translocate across the Plasma Membrane by Inducing Vesicle Budding and Collapse. Journal of the American Chemical Society. #IntavisPeptides #PeptideResearch #CellPenetratingPeptides

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐨𝐮𝐧𝐝𝐮𝐩 "𝐓𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐭𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐚𝐧𝐝 𝐟𝐮𝐭𝐮𝐫𝐞 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬" 𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐦𝐚𝐢𝐧 𝐭𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐝𝐢𝐬𝐜𝐮𝐬𝐬𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐩𝐚𝐩𝐞𝐫? The author identifies key trends in peptide drug discovery, particularly the rise of receptor agonists used in replacement therapies for naturally deficient or low-abundance hormones, such as Glp-1, GnRH, and GRF. These peptides act by mimicking biological regulators to treat conditions like diabetes, hormonal imbalances, and metabolic disorders. 𝐓𝐡𝐞 𝐬𝐮𝐜𝐜𝐞𝐬𝐬 𝐨𝐟 𝐭𝐡𝐞𝐬𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐢𝐬 𝐥𝐚𝐫𝐠𝐞𝐥𝐲 𝐝𝐮𝐞 𝐭𝐨 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐜𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲, including the strategic incorporation of non-natural amino acids and organic modifications, which enhance pharmacokinetic properties like stability, half-life, and tissue targeting. Additionally, dual and triple receptor agonists, such as Tirzepatide and Retatrutide, are being explored for their potential to target multiple clinical indications, further broadening the scope of peptide therapeutics. Paper reference: Otvos, L. (2024). The latest trends in peptide drug discovery and future challenges. Expert Opinion on Drug Discovery, 1-4. #PeptideDrugDiscovery #Peptides #Intavis

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐖𝐞𝐞𝐤𝐥𝐲 𝐏𝐨𝐥𝐥 When it comes to drug formulation, each element plays a vital role in ensuring safety and effectiveness. However, one component stands out as the cornerstone of the entire process. 𝐘𝐨𝐮𝐫 𝐢𝐧𝐩𝐮𝐭 𝐢𝐬 𝐯𝐚𝐥𝐮𝐚𝐛𝐥𝐞! #Intavis #Peptides

Dr. Christian Stumpp, MBA, Ph.D., our Head of Business Development, will be attending the BioRN Life Science Cluster Rhine-Neckar Annual Conference 2024, happening on October 9th at the Heidelberg Congress Center. It’s a great opportunity to connect with him and discuss possible collaborations in 𝐜𝐮𝐬𝐭𝐨𝐦 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬, 𝐆𝐌𝐏 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬, and 𝐧𝐞𝐨𝐚𝐧𝐭𝐢𝐠𝐞𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐯𝐚𝐜𝐜𝐢𝐧𝐞𝐬. Don’t miss the chance to connect with Dr. Stumpp directly. #BioRNConference2024 #Peptides #LifeSciencesNetworking

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐍𝐞𝐰𝐬 TREOS BIO LIMITED's meta-analysis from three clinical trials of its immunotherapy, PolyPEPI1018, for microsatellite stable metastatic colorectal cancer (MSS mCRC), will be presented at the 2024 ESMO meeting. The analysis revealed that HLA genotype plays a crucial role in predicting immune responses and clinical outcomes. Treos’ personalized epitopes, which bind to multiple HLA alleles, were more effective than traditional ones at activating T cells, correlating with tumor shrinkage and overall survival. The studies demonstrated PolyPEPI1018's potential in both early and late-stage MSS mCRC, with broader applications for other cancers under development. Intavis Peptide Services supports 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐟𝐫𝐨𝐦 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐭𝐨 𝐆𝐌𝐏 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭, contributing to groundbreaking treatment options in fields of high unmet medical need like colorectal cancer.  #PeptideNews #CancerImmunotherapy #Peptides

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭 Custom peptide synthesis has a crucial role in life sciences , particularly its use in drug discovery, diagnostics, and biotechnology. In this article, we highlights the broad applications of custom peptides across pharmaceuticals, diagnostics, and positioning custom peptide synthesis as a cornerstone in advancing medicine and biotechnology. Stay informed, Stay ahead with Intavis. September 2024: 𝐂𝐮𝐬𝐭𝐨𝐦 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐒𝐲𝐧𝐭𝐡𝐞𝐬𝐢𝐬 #CustomPeptideSynthesis #IntavisArticle

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐖𝐞𝐞𝐤𝐥𝐲 𝐏𝐨𝐥𝐥 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐦𝐨𝐝𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 are essential for enhancing their 𝐬𝐭𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐚𝐧𝐝 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐚𝐜𝐭𝐢𝐯𝐢𝐭𝐲, making them more effective in various applications, from research to clinical use. Different strategies are used to achieve these improvements, each with unique benefits. 𝐒𝐡𝐚𝐫𝐞 𝐲𝐨𝐮𝐫 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 on which modification you think is mostly common used! #Peptides #Intavis